AGENDA
Welcome & Introductions
8:00 - 8:15 am CT
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
PARP Inhibitor Treatment in Prostate Cancer
8:15 - 9:15 am CT | 1.0 CME/CE
Neeraj Agarwal, MD, FASCO
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
HCI Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, UT
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Paris, TX
Risk Stratification and Management of Myelodysplastic Syndrome
9:15 - 10:15 am CT | 1.0 CME/CE
Rami S. Komrokji, MD
Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, FL
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
Break
10:15 - 10:30 am CT
Gastric/GEJ Cancers: Navigating the Treatment Landscape
10:30 - 11:30 am CT | 1.0 CME/CE
Yelena Y. Janjigian, MD
Professor of Medicine
Weill Cornell Medical College
Chief Attending, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
Advances in Management of HER2-Mutant NSCLC
11:30 am - 12:30 pm CT | 1.0 CME/CE
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Lee Albright and Nile Albright MD Endowed Chair, Clinical Cancer Research
Massachusetts General Hospital Cancer Center
Boston, MA
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
Break
12:30 - 12:45 pm CT
Updates on TROP2-Targeted Antibody-Drug Conjugates in NSCLC
12:45 - 1:45 pm CT | 1.0 CME/CE
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Lee Albright and Nile Albright MD Endowed Chair, Clinical Cancer Research
Massachusetts General Hospital Cancer Center
Boston, MA
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
Evolving Treatment Paradigms in Hepatocellular Carcinoma
1:45 - 2:45 pm CT | 1.0 CME/CE
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Chris Prakash, MD
Medical Director
Texas Oncology - Paris
Paris, TX
Agenda as of 3/25/24. Session order subject to change.